NCT03542058|UnknownPhase 3
Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.
SATRACD
Loading search results
SATRACD
Sponsor study identifier
interventional
50
0 countries
N/A
Study Start
June 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The objective of this research is to describe the burden of subclinical anthracycline therapy related cardiac dysfunction( ATRCD) by applying international guideline on Uganda cancer patient and to evaluate the significance of treating subclinical ATRCD with carvedilol.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 18, 2018
Actual (reported)May 31, 2018
Actual (reported)June 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Cardiac function
This will be measured by mean GLS(Global Longitudinal strain) value.
6 months
Study participants will receive carvedilol for a period of 6 month. The initial dosage of carvedilol will be 3.125mg twice daily. Dosage will be titrated up two weekly until the maximum tolerable dose or ceiling dose of 25mg twice daily has been reached.
Study participant will not receive any cardiac medication, apart from standard cancer care.
Participants who are randomized to treatment group will receive carvedilol for a period of 6 month.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Karen Sliwa, PhD
Hatter Institute for Cardiovascular Disease in Africa
Feriel Azibani, PhD
Hatter Institute for Cardiovascular Disease in Africa
First Submitted
May 18, 2018
First Posted
May 31, 2018
Study Start
June 2018
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
June 2021
Estimated (date passed)Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 31, 2018
Record last verified: 2018-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: